Private Equity

Updated:

Alafi Capital

Alafi Capital is a San Francisco venture firm led by Christopher Alafi and Moshe Alafi, investing in early-stage biotech and deep-tech startups since the...

Alafi Capital

Alafi Capital is a private venture capital firm that has been active in healthcare investing for over 25 years. The firm considers early and mid-stage investments in the U.S. and Europe, focusing on product-oriented biotechnology, life science technologies, imaging and diagnostics, and medical devices. Alafi Capital has made 48 investments, including past successes such as Amgen and Biogen, and has 14 portfolio exits, including Bolt Threads.

General information

Firm type

Private Equity

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

San Francisco

Corporate office

San Francisco, CA, United States

Sector focus

Enterprise SoftwareAI/MLDigital Health

Frequently asked questions

Who makes investment decisions at Alafi Capital?

Christopher Alafi, who holds a PhD in molecular and cell biology from UC Berkeley, and his father Moshe Alafi jointly manage the firm. Investment decisions rely on Christopher Alafi's scientific training combined with Moshe Alafi's five decades of venture experience in biotechnology. The firm has not publicly disclosed a broader investment committee structure.

What is the relationship between Alafi Capital and the early biotech industry?

Moshe Alafi was a founding figure in biotechnology venture capital, co-founding one of the sector's first dedicated funds and serving as an early backer of Amgen and Applied Biosystems. Alafi Capital represents an extension of that legacy, with Christopher Alafi carrying forward the family's specialization in science-driven, early-stage investing. This historical positioning gives the firm a deep network within academic research institutions and biotech ecosystems.

What investment stages does Alafi Capital target?

The firm focuses on seed and start-up stage investments, per its own communications. This places Alafi Capital at the earliest inflection point for companies originating from university research labs. The firm typically engages when intellectual property is still being translated into a commercial entity, often before a full management team is in place.

Does Alafi Capital invest outside of biotechnology?

While biotechnology and life sciences form the historical core of the Alafi portfolio, the firm has also selectively backed enterprise software and AI/ML companies with biological or healthcare applications. The unifying thread is technical complexity and scientific defensibility, not a single industry category. The team's primary competence remains at the intersection of biology and engineering.

How does Alafi Capital source its deals?

The firm's deal flow is heavily relationship-driven, leveraging generational ties to University of California campuses, particularly UC Berkeley and UCSF, as well as Stanford. Moshe Alafi's reputation as a biotech venture pioneer provides access to seasoned scientific founders, while Christopher Alafi's PhD background enables credible technical evaluation of early-stage research. This dual-pronged sourcing has sustained the firm without a large business development function.

Is Alafi Capital structured as a single family office or a traditional venture firm?

Alafi Capital is structured as an asset manager and venture firm rather than a single family office. It operates with external limited partners and fund vehicles, though the Alafi family maintains significant personal capital in the funds. This hybrid of family capital and institutional structure is common among multi-generational venture firms with deep domain specialization.

What is Alafi Capital's known posture on follow-on investments?

The firm does not publicly disclose a formal follow-on policy. Given its early-stage focus and lean team, Alafi Capital is known for concentrated initial positions with selective follow-on participation. The Alafis typically retain board seats and support portfolio companies through subsequent financings, often alongside larger venture syndicates that they help assemble.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More San Francisco Private Equity profiles